Karonudib for leukemia that has come back or not responded
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 trial studies Karonudib, a new treatment, for people with leukemia (and a few related blood cancers) that has come back or didn’t respond to standard care. The goal is to see if the treatment is safe and to learn how it may work in this hard-to-treat setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent (or you have a legal representative who can).
- You are 18–75 years old (sometimes older if the study doctor thinks it’s safe).
- Your leukemia or related blood cancer has returned or is resistant, and standard treatments aren’t working or aren’t an option.
- You need to have disease that can be measured (in blood, bone marrow, or scans).
- Your heart and organ function must be strong enough for study treatment (including normal heart pumping and enough kidney/liver function).
- You must be able to take pills by mouth and have enough blood counts (platelets and other basic blood measures).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a combination of two chemotherapy drugs packaged in a special fat coating (liposome) plus a targeted pill called venetoclax for adults with acute myeloid leukemia (AML) that has come back, not responded, or is newly diagnosed. The goal is to see if this combination is safe and effective.
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This Phase 1 trial tests keynatinib, a new medicine, in people with specific types of lymphoma that have returned or not responded to earlier treatment. It aims to find a safe dose and see whether it can shrink tumors in the brain or elsewhere in the body, depending on the group.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.